2011 Press Releases Communiqués de presse

December 23, 2011 23 December, 2011

Sernova Provides Summary of 2011 Accomplishments and Corporate Update for 2012

November 17, 2011 17 November, 2011

Sernova Retains Investor Relations Firm Russo Partners LLC

October 25, 2011 25 October, 2011

Sernova Enters Into Collaboration With Edmonton's Clinical Islet Transplant Program To Expand Cell Pouch(tm) Applications For Diabetes Treatment

October 17, 2011 17 October, 2011

Sernova Announces Extension of Terms of Warrants

October 4, 2011 4 October, 2011

Sernova to Present at Biopartnering Europe Conference

September 1, 2011 1 September, 2011

Sernova Announces Closing Of Non-Brokered Private Placement

July 18, 2011 18 July, 2011

Sernova to be Granted Australian Patent

June 24, 2011 24 June, 2011

Sernova Announces Closing of $1 Million Brokered Private Placement and Provides Corporate Update

June 6, 2011 6 June, 2011

Sernova Corp Presents Key Data at International Transplant Conference

May 5, 2011 5 May, 2011

Sernova Cell Pouch System™ Demonstrates Islet Sparing Potential In Diabetes Model

March 3, 2011 3 March, 2011

Sernova To Present Cell Pouch System™ Research Results At Transplantation Conference

February 28, 2011 28 February, 2011

Sernova Reports Positive Cell Pouch™ Performance In A Non-Human Primate Study

February 25, 2011 25 February, 2011

Sernova To Present At BioPartnering North America Conference

January 12, 2011 12 January, 2011

Sernova To Present At The OneMedForum San Francisco 2011 Conference

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - December 23, 2011 23 December, 2011

Sernova Provides Summary of 2011 Accomplishments and Corporate Update for 2012


-- Company Plans to Initiate Patient Enrollment in a Phase I/II Clinical Trial and Participate with a Leading Research Center in Grant Submissions to Explore Further Applications for the Cell PouchTM System --

December 23, 2011, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire -- Dec. 23, 2011) - Sernova Corp. (TSX-V: SVA), is pleased to provide a synopsis of accomplishments for 2011 including an update on clinical development of the Cell PouchTM and projections for 2012.

Cell PouchTM Preclinical Update

Sernova completed its preclinical studies for the diabetes indication. The Cell PouchTM placed in the subcutaneous space in four different animal models consistently demonstrated incorporation with tissue and microvessels, creating an ideal natural environment for therapeutic cell transplantation. This consistent behavior of the Cell PouchTM in multiple animal models has previously never been observed and has inspired the experts to participate in a clinical trial.

In the latest large animal study, the Cell PouchTM demonstrated excellent safety and efficacy using 25 percent of the islet cells typically used in the Edmonton Protocol. The study, partially funded by a $250,000 contribution from NRC- IRAP, mimicked the Edmonton Protocol in an allograft diabetes model using donor islets transplanted into the Cell PouchTM and an antirejection drug regimen. Importantly, robust microvessels integrated with the islets, a hallmark of natural functioning islets.

The Cell PouchTM has kept diabetic animals insulin- independent for 6 months (the study length) demonstrated in an isograft small animal model. This study, along with the autograft and allograft studies provide strong evidence for the long-term safety and efficacy of the Cell PouchTM and a strong rationale for its evaluation in humans with diabetes.

The study results were presented at various medical research events including a podium presentation at the 13th World International Pancreas and Islet Transplantation Conference in Prague, a premier meeting for preeminent islet transplantation surgeons and scientists.

Cell PouchTM Clinical Evaluation Update

Based on these exemplary preclinical results, Sernova is preparing for human clinical studies where patients with diabetes will be implanted with the Cell PouchTM, transplanted with donor islets. The following is an update of progress.

In Sernova's discussions with Health Canada, importantly, the Cell PouchTM has been designated as a Medical Device for regulatory purposes.

Dr. James Shapiro (University of Alberta, Edmonton) developer of the Edmonton Protocol is principal clinical investigator for the diabetes study. Sernova's team has been preparing documents for submission to Health Canada and working closely with Dr. Shapiro's team developing the clinical protocol and other documents required for the Research Ethics Board (REB) at the University of Alberta.

Sernova hired Ethox Corporation, a division of Moog Inc. of Buffalo, N.Y., as product contract manufacturer. The Cell PouchTM, manufactured under strict regulatory guidelines (ISO13485:2003) will be suitable for testing in clinical trials in North America and Europe. Manufacture is being conducted using a semi-automated process to ensure strict quality control. The manufacturing process, specifications, packaging, and sterilization processes have been set. Manufacturing of the clinical Cell PouchTM product is under way.

For entry into clinical trials, a series of biocompatibility studies have been conducted according to ISO10993 guidelines, assessing the compatibility of the Cell PouchTM with the body. With virtually all of the testing completed, the Cell PouchTM performed extremely well, satisfying the requirements.

CanReg (Optum Insight) is working with Sernova to complete the regulatory filing for Health Canada. Optum Insight is a global regulatory consulting company for the pharmaceutical, biotechnology and medical device industries with over 100 in-house consultants and staff serving clients in the United States, Canada, Europe and Asia. Optum Insight is very experienced with successful Health Canada regulatory document filing and clinical trial approval for medical devices.

Sernova Proposed Development 2012

Sernova plans to complete the following objectives in 2012:

Filing documentation in Q1 with the University of Alberta REB, part of the approval process for Dr. Shapiro to conduct the clinical study

Filing of regulatory documentation with Health Canada in Q1, which upon clearance will enable initiation of the clinical study

Completion of Cell PouchTM manufacture and sterilization validation processes and release of clinical product in Q1for the clinical trial

Initiating patient enrollment in the clinical trial with Dr. Shapiro in Q2

Application for additional grants for work on local cell protector technology and for the collaboration with Dr. Shapiro to assess next generation products related to the Cell PouchTM in Q1

Additional collaborations with islet transplantation centers towards further clinical evaluation of the Cell pouchTM

Development of corporate collaborations to assess stem cell and other technologies in the Cell PouchTM

Continue discussions with potential business partners towards a licensing deal

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - November 17, 2011 17 November, 2011

Sernova Retains Investor Relations Firm Russo Partners LLC


Source: Sernova Corp

November 17, 2011, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire -- November 17, 2011) - Sernova Corp. (TSX-V: SVA), is pleased to announce that it has retained Russo Partners LLC, a leading healthcare communications company with over 23 years of experience, to provide investor relations services to Sernova.

"Russo Partners has extensive experience and a proven track record in healthcare communications as well a deep pool of institutional investor contacts. We look forward to working with Russo as Sernova is poised to transition from a preclinical to a clinical stage company with an international presence," said Dr. Philip Toleikis, Ph.D., President and CEO of Sernova.

Russo Partners will work closely with Sernova's management on all facets of the company's communication strategy, including Sernova's positioning and messaging. Russo Partners will also secure presentation opportunities, media interviews and investor meetings for the company during first quarter of 2012.

Pursuant to the investor and public relations agreement, which is subject to the acceptance of the TSX Venture Exchange, Sernova will pay Russo Partners a monthly fee of $8,000 plus a one-time fee of $15,000 in two monthly installments. The agreement may be terminated by either party on 30 days notice.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

About Russo Partners LLC

Russo Partners is a U.S.-based corporate communications firm with a proven track record in providing strategic and effective communications counsel to companies in the healthcare sector. Russo Partners connects its clients with the audiences that matter the most: investors, business partners, physicians and patients. The Russo Partners team consists of senior PR counselors with Ph.D.s, M.D.s and M.B.A.s.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251 tony.russo@russopartnersllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 25, 2011 25 October, 2011

Sernova Enters Into Collaboration With Edmonton's Clinical Islet Transplant Program To Expand Cell Pouch(tm) Applications For Diabetes Treatment


Source: Sernova Corp

LONDON, ONTARIO - (Marketwire - October 25, 2011) - Sernova Corp. (TSX-V: SVA), is pleased to announce it has entered into a collaboration with The Clinical Islet Transplant Program at the University of Alberta Hospital.

The Program is headed by Dr. James Shapiro, MD, Ph.D. FRCS (Eng) FRCSC, the leader of the team that developed the Edmonton Protocol, the current standard of care for islet transplantation. In September 2010, following review of Sernova's preclinical data, Dr. Shapiro joined the Corporation's Scientific Advisory Board.

"Dr. Shapiro's contributions to date position us to enter into this important collaboration which is targeted to expand access to islet transplantation for the treatment of diabetes to a much wider base of patients using Sernova's Cell Pouch(tm)," said Dr. Philip Toleikis, Ph.D., President and CEO of Sernova.

The current procedure for islet transplantation to treat diabetes, commonly known as the "Edmonton Protocol" involves transplanting islets directly into a blood vessel (portal vein) of the liver. The Cell Pouch(tm) is expected to solve a number of issues arising from portal vein delivery. For example, the Cell Pouch(tm) provides a natural setting where blood vessels grow adjacent to the islets rather than being bathed in blood which can result in the death of up to 75% of the islets through an instant blood mediated inflammatory response (IBMIR). Use of the Cell Pouch(tm) would eliminate portal vein hypertension and thrombosis associated with portal vein islet delivery and potentially reduce the cost of the procedure as the catheterization laboratory is not required for implantation of the Cell Pouch(tm) or islet transplantation. Importantly, preclinical studies of the Cell Pouch(tm) have consistently shown excellent safety and efficacy profiles with significantly fewer islets than for portal vein delivery, which could increase the number of recipients treated with the current donor pool. Furthermore, implantation of the Cell Pouch(tm) just under the skin allows for imaging of the islets and microvessels and for local immunoprotection of therapeutic cells.

Sernova's Cell Pouch(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, the Cell Pouch(tm) develops pancreas-like function when infused with islets, controlling blood sugar levels as shown by published preclinical data which also suggests that the natural environment promotes cell survival reducing the number of islets required for therapy.

Sernova is currently pursuing upcoming human testing of the Cell Pouch(tm) based on the strong preclinical safety and efficacy data generated to date.

This collaboration will further seek to position the Cell Pouch(tm) through next generation improvements to the Edmonton Protocol to expand access to cell transplant to a much wider patient population. The collaboration will include work related to: Assessment of islet protective agents that could further reduce the islet mass required for each transplant using the Cell Pouch(tm)

Assessment of locally administered anti-rejection strategies within the Cell Pouch(tm) with the goal of reducing or eliminating systemic antirejection regimens

Assessment of a proprietary, ethically derived insulin- producing stem cell technology within the Cell Pouch(tm) as an enabling technology which could significantly expand the number of patients treated

Development of high resolution imaging systems to enable physicians to better assess and optimize long- term islet function A video describing the Edmonton Protocol and the collaboration of Sernova with Dr. Shapiro may be viewed on Sernova's website at www.sernova.com

"The safety and efficacy of the Cell Pouch(tm) in preclinical studies is impressive. We are excited to be working with Sernova in both preparing for its upcoming clinical trial and in this collaboration. We are hopeful that Sernova's Cell Pouch(tm) will significantly increase the number of diabetic patients that can be treated with islet transplantation," said Dr. Shapiro, Director of the Clinical Islet Transplant Program, at the University of Alberta and member of Sernova's Scientific Advisory Board.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 17, 2011 17 October, 2011

Sernova Announces Extension of Terms of Warrants


LONDON, ONTARIO -- October 17, 2011 -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA) announces that it proposes to extend the term of common share purchase warrants that were issued pursuant to a non-brokered private placement of units of the Company (the "Private Placement") on October 30, 2009.

A total of 3,659,000 units (the "Units") were issued in the 2009 Private Placement, each Unit consisted of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"), with each Warrant entitling the holder thereof to acquire one additional Common Share at a price of $0.20 per Common Share. The Warrants are scheduled to expire on October 30, 2011. Subject to TSX Venture Exchange approval, the expiration of the 3,659,000 Warrants will be extended to 4:00 p.m. (Pacific Time) on April 30, 2012.

No Warrants have been exercised to date.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch SystemTM and its patented SertolinTM cell technology.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 04, 2011 4 October, 2011

Sernova to Present at Biopartnering Europe Conference


Source: Sernova Corp.

LONDON, ONTARIO--(Marketwire -- October 4, 2011) - Sernova Corp. (TSX VENTURE:SVA) today announced that the Company will present to a select group of biotech industry investors and potential alliance partners at the BioPartnering Europe Conference, in London, England, at 2:30 p.m. at the QE II Conference Center on October 10th, 2011.

Sernova's President & Chief Executive Officer, Dr. Philip Toleikis, will provide an update on Sernova's recent advances including pre-clinical studies, contract manufacturing for clinical studies and progress towards advancement of the Company's Cell Pouch SystemTM into human clinical trials. Sernova Corp was sponsored for this conference in part by the Ontario Ministry of Economic Development and Trade and is part of the Ontario mission to BioPartnering Europe.

"With the consistent preclinical results demonstrating insulin independence using the Cell PouchTM in multiple preclinical models of diabetes and upcoming evaluation in diabetic patients, BioPartnering Europe provides an ideal venue to showcase Sernova's ground breaking technologies and conduct one on one meetings with potential corporate alliance partners and investors," said Dr. Philip Toleikis, President and CEO of Sernova Corp.

The Cell Pouch SystemTM is a proprietary medical device which may offer a significant improvement over the current practice of injecting therapeutic cells into blood vessels. Based on pre-clinical studies in four models, the Cell Pouch SystemTM becomes a vascularised organ-like endocrine structure when placed in the body under the skin, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in stringent small and large animal models of diabetes and has shown the device with insulin-producing islets controls blood glucose levels long-term, eliminating the need for daily insulin injections. This has now been demonstrated in isograft, autograft (self-tissue) and allograft (donor tissue) studies using substantially lower doses of islets than typically used for portal vein delivery, the current standard of care. Furthermore, Sernova believes the Cell Pouch SystemTM has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases and is currently seeking corporate partnerships as part of a strategy to demonstrate the broad utility of the Cell Pouch SystemTM.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch SystemTM to provide a safe and efficacious environment for therapeutic cells and SertolinTM, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 01, 2011 1 September, 2011

Sernova Announces Closing Of Non-Brokered Private Placement


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

LONDON, ONTARIO--(Marketwire - September 1, 2011) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce the closing of a non-brokered private placement of 1,510,002 units of the Company ("Units") at a price of $0.19 per Unit for gross proceeds of approximately $286,900 (the "Offering"). Together with the approximate $1,014,200 raised in the offering that closed on June 24, 2011, this summer Sernova has closed a total of approximately $1,301,100.

Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share for a period of two years, at a price of $0.20 per Share in the first year and at a price of $0.35 per Share in the second year.

In connection with the Offering, the Company issued 90,410 finder's warrants ("Finder's Warrants") and approximately $17,178 was paid to a finder. Each Finder's Warrant entitles the holder thereof to purchase one Share at a price of $0.19 per Share for a period of 18 months from closing of the Offering.

The proceeds from the Offering will be used by Sernova for further development of the Cell PouchTM for safety and efficacy evaluation in diabetic patients receiving donor islets. Proceeds will also be used in part for potential university and corporate collaborations, additional preclinical studies and general and administrative activities.

All securities issued under the private placement will be subject to a four month hold period, expiring January 1, 2012, during which time the securities may not be traded. The Offering is subject to acceptance by the TSX Venture Exchange.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch SystemTM and its patented SertolinTM cell technology.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - July 18, 2011 18 July, 2011

Sernova to be Granted Australian Patent


LONDON, ONTARIO (Marketwire - July 18, 2011) - Sernova Corp (TSX VENTURE:SVA) is pleased to report that the Australian Patent Office has issued a Notice of Allowance for a patent entitled "Compositions Containing Sertoli Cells and Myoid Cells and Use Thereof in Cellular Transplants." Allowance in additional international jurisdictions including Canada, Europe, Japan and the United States is pending.

"The allowance of this patent continues to add to our extensive portfolio of over 22 issued and pending patents covering our cell-therapy enabling platform, including the Cell Pouch System(TM)," said Dr. Philip Toleikis, Sernova's President and CEO. "The broad claims in this patent position us with the ability to expand our platform to a wide range of therapeutic cell types important in treating chronic disease. Broadening our patent portfolio also positions us to maximize partnering and development opportunities as we continue to advance our Cell Pouch System(TM) toward human clinical studies."

Sernova has presented evidence at leading scientific conferences demonstrating that the Cell Pouch System(TM) can be used as an effective platform for delivery of insulin from both autograft (self) and allograft (donor) islets to restore glucose control in stringent preclinical models of diabetes. According to the American Diabetes Association, diabetes is the sixth leading cause of death in the United States with approximately 9 million Americans requiring daily insulin injections. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

In the future, Sernova plans to explore the additional utility of the Cell Pouch System(TM) as an enabling platform for a range of therapeutic cell types with the potential to treat a number of chronic debilitating diseases representing broad unmet medical needs.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 24, 2011 24 June, 2011

Sernova Announces Closing of $1 Million Brokered Private Placement and Provides Corporate Update


THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Source: Sernova Corp

LONDON, ONTARIO--(Marketwire - June 24, 2011) - Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA - News) is pleased to announce the closing of its brokered private placement announced May 10, 2011. 5,337,914 units of the Company ("Units") were placed at a price of $0.19 per Unit for gross proceeds of approximately $1,014,200 (the "Offering"). Each Unit will consist of one common share of the Company (a "Share") and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Share for a period of two years, at a price of $0.20 per Share in the first year and at a price of $0.35 per Share in the second year.

Macquarie Private Wealth Inc. (the "Agent") acted as agent in connection with the Offering. The Agent received a commission of $29,693.20, representing 8% of the gross proceeds raised on subscribers introduced to the Offering by the Agent ("Non-President's List Subscribers", with all other subscribers being "President's List Subscribers") and 6% of the gross proceeds from two President's List Subscribers (the "President's List Commission"), a corporate finance fee of $25,000 (plus applicable taxes), and broker warrants (the "Broker Warrants") to acquire 195,950 Shares, being 10% of the Units sold under the Offering to Non-President's List Subscribers. Each Broker Warrant will be exercisable at $0.19 per Share for a period of 18 months following the closing. 3,474,414 Units were issued to President's List Subscribers and the Agent did not take any commission or Broker Warrants with respect to the President's List Subscribers, with the exception of the above-mentioned President's List Commission.

The proceeds from the Offering will be used by Sernova for further development of the Cell Pouch(tm) for safety and efficacy evaluation in diabetic patients receiving donor islets. Proceeds will also be used in part for potential university and corporate collaborations, additional preclinical studies and general and administrative activities.

All securities issued under the private placement will be subject to a four month hold period, expiring October 24, 2011, during which time the securities may not be traded.

Sernova also wishes to announce the resignation of Dr. Annemarie Moseley from the Board of Directors. Dr. George Adams, Chair of Sernova's Board stated, "The company has greatly benefited from Dr. Moseley's excellent council and wishes her well in her future endeavours as she focuses on her stem cell company."

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(tm) and its patented Sertolin(tm) cell technology.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 06, 2011 6 June, 2011

Sernova Corp Presents Key Data at International Transplant Conference


COMPANY'S PRESENTATION SUMMARIZES POSITIVE ISLET SPARING RESULTS USING ITS CELL POUCH SYSTEM(tm) IN AN ALLOGRAFT ISLET TRANSPLANT DIABETES MODEL

Source: Sernova Corp

FOR RELEASE

LONDON, ONTARIO (Marketwire - June 6, 2011) - Sernova Corp (TSX VENTURE:SVA) is pleased to report positive results from a key study demonstrating the islet sparing capacity of the Cell Pouch System(tm) implanted with donor islets (allograft) in a model of diabetes.

Dr. Philip Toleikis, Sernova's President & CEO stated, "These data confirm that our Cell Pouch System(tm) provides an excellent safety and efficacy profile using a minimal dose of islets and an antirejection drug regimen to prevent rejection of the islets in the graft."

Sernova Corp was invited to deliver a podium presentation to leading diabetologists, pancreas and islet transplant clinicians and scientists this past weekend at the 13th World Congress of the International Pancreas and Islet Transplant Association Conference (IPITA), Prague, Czech Republic held June 1-4th in a presentation entitled, "Islet Sparing Potential of a Subcutaneous Cell Pouch(tm) for Allogeneic Islet Transplantation."

Important findings reported by Sernova include: Glucose control was achieved using the Cell Pouch System(tm) at the lowest dose of islets transplanted, about 25% of the islets typically used in other international clinical islet transplantation programs. . Islet transplanted animals were C-peptide positive, a gold standard measure of islet released insulin glucose control. Presence of insulin in the islets within the Cell Pouch System(tm) was confirmed by insulin staining. Treated diabetic animals maintained good health including stable body weight confirming the effectiveness of the Cell Pouch System(tm) transplant. No adverse events related to the Cell Pouch System(tm) occurred during the study. "This represents another significant preclinical safety and efficacy study of the Cell Pouch System(tm). We have now also confirmed in four controlled pre-clinical studies the robust tissue and microvessel development suitable for therapeutic cell transplant," stated Dr. Philip Toleikis, President and CEO of Sernova Corp.

"Sernova has strong evidence that the Cell Pouch System(tm) as a platform technology is efficacious for autograft (self-tissue) transplants and could potentially be used to restore glucose control in chronic pancreatitis patients and for allograft (donor tissue) transplants for established diabetics administered an antirejection regimen. These consistent findings in multiple studies strongly support the advancement of the assessment of the Cell Pouch System(tm) into human clinical studies," stated Toleikis.

About the Study

The Cell Pouch System(tm) was implanted in adult Gottingen minipigs which were then made diabetic through a dose of streptozotocin. Animals were given Sirolimus and cyclosporine beginning several days prior to implantation of donor islets (Allograft) isolated from the pancreas of Yorkshire Landrace adult pigs. Standard measures of efficacy including fasting and non- fasting glucose levels, glucose tolerance tests (IVGTT), and C- peptide were taken up to the end of the study post- transplant. At the end of the study period, the devices containing the islets were removed and the animals returned to a diabetic state.

Following transplantation, within the low dose islet transplantation group, study animals maintained glucose levels within the normal range, showed glucose tolerance tests (IVGTT) similar to non-diabetic animals and were C- peptide positive, an important confirmation of insulin- producing islet function. Microscopic fluorescence analysis of the devices revealed robust insulin staining associated with islets.

Upon removal of the Cell Pouch System(tm) containing islets, fasting glucose levels returned to the diabetic range and animals required daily insulin injections to maintain normal glucose levels. The animals' return to the diabetic state was further confirmed by IVGTT and C- peptide analysis.

From a safety perspective, no adverse events occurred related to the Cell Pouch(tm) throughout the study following implantation. The devices were well- incorporated with tissue matrix and yet were not visible under the skin, an important consideration for patients.

Sernova believes the Cell Pouch System(tm) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, and other chronic debilitating diseases. Based on these encouraging results, the Company is taking steps towards clinical evaluation of its Cell Pouch System(tm). The current study is supported in part through a non-repayable financial contribution of up to $275,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC- IRAP).

According to the American Diabetes Association, approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every eight dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(tm) to provide a safe and efficacious environment for therapeutic cells and Sertolin(tm), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - May 05, 2011 5 May, 2011

Sernova Cell Pouch System™ Demonstrates Islet Sparing Potential In Diabetes Model


DATA TO BE PRESENTED AT THE WORLD CONGRESS OF THE INTERNATIONAL PANCREAS AND ISLET TRANSPLANT ASSOCIATION

Source: Sernova Corp

FOR RELEASE

LONDON, ONTARIO--(Marketwire - May 5, 2011) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce the Company will present preliminary results of its ongoing islet sparing study with its Cell Pouch System(TM), in a late breaking session at the 13th World Congress of IPITA (International Pancreas and Islet Transplant Association), held June 1-4, 2011. Prague, Czech Republic.

This key international conference is held every two years and brings together the worlds eminent scientists and clinicians working to improve the lives of diabetic patients through islet transplantation. Sernova will be making a podium presentation entitled:

"Islet Sparing Potential of a Subcutaneous Cell Pouch(tm) for Allogeneic Islet Transplantation"

In this study, different doses of donor islets were transplanted into the prevascularized Cell Pouch(TM) placed in recipient diabetic animals. Doses ranged from 25% to the full standard of care dose of 10,000 IEQ/kg. Animals were then administered anti-rejection therapy to prevent graft rejection. Efficacy is assessed through standard measures of graft function including glucose tolerance tests, and C-peptide among other measures prior to and after implantation of islets and following Cell Pouch(TM) removal. For example, if a 25% dose were successful, use of the Cell Pouch(TM) could increase the number of transplant recipients by approximately 400% for the current donor pancreas pool.

Dr. James Shapiro, a member of Sernova's Scientific Advisory Board and eminent transplant surgeon at the University of Alberta stated "Positive results from this study would provide further compelling evidence to advance Sernova's Cell Pouch(TM) into human clinical trials. Confirmation of the islet sparing capacity of the Cell Pouch(TM) would be an additional benefit which could eventually allow treatment of more patients using the current donor islet pool."

Under the current standard of care for islet transplant patients, known as the Edmonton Protocol, donor islets are injected directly into the portal vein of the liver. This process is believed to stimulate an instant blood- mediated reaction (IBMIR) which is thought to destroy insulin- producing islets and may lead to further side effects for patients. The Cell Pouch(TM) avoids this reaction because islets are placed in a natural organ-like environment rather than directly into the bloodstream, and could lead to the need for fewer donor islets to achieve efficacy.

The safety and efficacy of the Cell Pouch(TM) has recently been demonstrated in an autograft setting where diabetic animals implanted with the human scaled prevascularized device became insulin independent when their own islets were removed and placed into the Cell Pouch(TM). The study provided efficacy with surprisingly far fewer functional islets than typically required, suggesting the Cell Pouch(TM) may be islet sparing.

The current study is supported in part through a non- repayable financial contribution of up to $275,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 03, 2011 3 March, 2011

Sernova To Present Cell Pouch System™ Research Results At Transplantation Conference


Source: Sernova Corp

FOR RELEASE

March 3, 2011, 6:00 a.m. EST

LONDON, ONTARIO--(Marketwire - March 3, 2011) - Sernova Corp. (TSX VENTURE:SVA) is pleased to announce the Company will present results of preclinical studies with its Cell Pouch System(TM), at the Canadian Society of Transplantation 2011 Annual Scientific Conference at Mt-Tremblant, Quebec, Canada held March 2-5.

The conference brings together eminent scientists and clinicians in the cell and organ transplantation field from across Canada and around the world. Sernova will be making three poster presentations entitled:

"The establishment of a stringent large animal model of insulin-dependent diabetes"

"A subcutaneous Cell Pouch(TM) as an alternative to intraportal infusion of islets of Langerhans to restore carbohydrate control in the diabetic recipient," and

"Islets transplanted into a subcutaneous Cell Pouch(TM) demonstrate long-term efficacy measured by C- peptide."

"The conference provides a venue to discuss the attributes of Sernova's novel Cell Pouch System(TM) as an alternate site for insulin-producing islet transplantation and its potential for additional cellular therapies with leaders from the medical transplantation community," stated Delfina Siroen, Sernova's Research and Development Head.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 28, 2011 28 February, 2011

Sernova Reports Positive Cell Pouch™ Performance In A Non-Human Primate Study


Source: Sernova Corp

February 28, 2011, 6:00 a.m. EST

LONDON, ONTARIO - (Marketwire - February 28, 2011) - Sernova Corp. (TSX VENTURE:SVA) today announced positive performance of its proprietary Cell Pouch System(TM) in a non-human primate study.

As a precursor to planned human trials with the device, the study, conducted in collaboration with the University of Illinois Transplant Biology Research Laboratory, was designed to further investigate the safety profile of Sernova's Cell Pouch System(TM) and its ability to develop a natural environment for therapeutic cells in the primate. In previous large animal studies, the Cell Pouch System(TM) was demonstrated to become rapidly vascularized and form a hospitable environment for therapeutic cells.

In the current study, a number of Cell Pouches were implanted under the skin of the Cynomolgus monkey in a minimally invasive procedure mimicking the technique to be used in upcoming human trials.

In Summary: The Cell Pouches were virtually undetectable under the skin following implantation, an important aesthetic characteristic for human use.

The safety profile of the Cell Pouch(TM) was exemplary throughout the eight week study with no skin irritation, no inflammation and no infections.

At the time of removal, the Cell Pouches(TM) at all assessment time points (2, 4 and 8 weeks) were well- incorporated with collagen and tissue, had well- established blood supplies and formed intra- pouch cavities suitable for therapeutic cell transplantation. These key features of the Cell Pouch(TM) are believed to provide for long-term survival of therapeutic cells demonstrated in Sernova's efficacy studies.

"These results in the non-human primate strengthen the potential of the Cell Pouch(TM) for human clinical trials, supporting previously reported findings of the formation of a natural, safe and efficacious environment for cell implantation in small and large animal models of diabetes," said Dr. Shapiro, Director of the Clinical Islet Transplantation Program at the University of Alberta and member of Sernova's Scientific Advisory Board.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases.

According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 25, 2011 25 February, 2011

Sernova To Present At BioPartnering North America Conference


Source: Sernova Corp.

February 25, 2011, 6:00 a.m. EST

LONDON, ONTARIO - (Marketwire - February 25, 2011) - Sernova Corp. (TSX VENTURE:SVA) today announced that the Company will present to a select group of biotech industry investors and potential alliance partners at the BioPartnering North America Conference in Vancouver, British Columbia at 10:45 a.m. on March 1, 2011.

Sernova's President & Chief Executive Officer, Dr. Philip Toleikis, will provide an update on the Sernova's recent progress including recent pre-clinical studies, manufacturing and plans for advancement of the Company's Cell Pouch System(tm) into human clinical trials.

The Cell Pouch System(TM) is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System(TM) becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System(TM) has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases and is currently seeking corporate partnerships as part of a strategy to demonstrate the broad utility of the Cell Pouch System(tm).

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 12, 2011 12 January, 2011

Sernova To Present At The OneMedForum San Francisco 2011 Conference


Source: Sernova Corp.

Wednesday, January 12, 2011, 6:00 a.m. EST

LONDON, ONTARIO - (Marketwire - January 12, 2011) - Sernova Corp. (TSX-V:SVA), a company focused on product development and commercialization of innovative medical technologies for cell therapies, is pleased to announce that its President & Chief Executive Officer, Dr. Philip Toleikis will present an overview of the company's technology and strategic positioning to a select group of biotech industry investors at the OneMedForumSF 2011, Emerging Company Finance Conference on Wednesday, January 12, 2011 at 2:00 p.m. (PT) at the Sir Francis Drake Hotel in San Francisco, California.

OneMedForum takes place January 11-13, 2011 in San Francisco, CA during the world's largest gathering of healthcare financiers and executives. The Forum will feature presentations by over 100 of the world's most promising emerging life science public and private companies. In 2010, over 1,000 investors participated in the conference. To learn more about the forum, visit www.onemedplace.com.

Sernova's Cell Pouch System(tm) is a scalable medical device providing a natural "organ-like" environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas when infused with islets. The natural environment established by the Cell Pouch System(tm) is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

About Sernova

Sernova Corp. is a Canadian-based, health- sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin- dependent diabetes, using the novel Cell Pouch System(TM) and its patented Sertolin(TM) cell technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. One out of every 8 dollars spent on health care in the United States is spent on treating diabetes and its complications. Worldwide expenditures on insulin alone are estimated to be $15 billion annually and growing.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 info@sernova.com www.sernova.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities - that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.